However, further research is warranted to elucidate the clinical impact of CFTR modulators, particularly due to limitations in sample size in several studies, and to comprehensively understand the alterations in the respiratory microbiome influencing Af dynamics in CF patients. The gene discussed is CFTR; the disease is cystic fibrosis.